Global Tumor Ablation Market- By Technology (Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation Ablation, Cryoablation, and Other Ablation Technologies), By Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, and Percutaneous Ablation), By Application (Liver Cancer, Kidney Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, and Other Applications), By End-User (Speciality Clinics, Ambulatory Surgery Centers, Hospitals, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 21174
- Number of Pages: 285
The Global Tumor Ablation Market size is expected to be worth around USD 4,389 Million by 2032 from USD 1,333 Million in 2022, growing at a CAGR of 13% during the forecast period from 2023 to 2032.
Tumor ablation is a minimally invasive process used to treat malignancies in the liver, bones, kidneys, and lungs. A generator and a device resembling a needle are the components of the ablation system. The device delivers heat directly to the target cells, causing severe cellular necrosis. Under Precise Computer Tomography, a probe is inserted and heated to 100 degrees Celsius to kill benign tumors without removing them from the body. Cryoablation, radiofrequency ablation, and other techniques can be utilized. It causes less pain, covers a larger area of treatment, it is more accurate, and poses less risk to the patient when used frequently.
Major contributors to the market’s expansion are the rising incidence of cancer and the strong demand for safer treatments. By 2032, the World Health Organization predicts that 10-11 million new cases of cancer will be diagnosed worldwide annually. It is anticipated that under-developed countries will see an increase in the number of new cases of cancer of more than 80%, compared to a rate of 40% in developed countries. The market is estimated to be driven in the coming years by the high demand for minimally and non-invasive therapies and the lucrative growth potential of the therapeutic options that are currently available.
*Actual Numbers Might Vary In The Final Report
- Rising Cancer Incident: Cancer has become more prevalent globally and Tumor Ablation procedures offer minimally invasive solutions for treating cancer that may not qualify for surgery or other traditional forms of treatments. As such, their market is growing.
- Minimally Invasive Techniques: Tumor ablation procedures such as radiofrequency ablation, microwave ablation and cryoablation have become more popular due to their minimally invasive nature and potential benefits such as reduced post-operative complications, shorter recovery periods and improved patient outcomes.
- Tumor Ablation Applications Have Grown: Tumor ablation techniques have expanded their applications by targeting liver, lung, kidney and bone tumors as cancer types evolve over time. This trend contributes to market expansion.
- Technological Advancements: Continuous technological progress has increased both precision and effectiveness of tumor ablation procedures, including robotics, real-time imaging technology, and better catheter technologies that enhance precision, accuracy, safety, and efficacy of treatments for this cancerous mass.
- Patient-Centric Approach: As the healthcare market shifts toward personalized treatment plans for its customers, tumor ablation procedures can now be customized specifically to each patient and can increase quality care overall.
Technological Advancement in Ablation Devices
The growing technological advancement of ablation devices is one of the major drivers of the market. The acceptance of tumor ablation techniques has increased with the introduction of thermal and laser ablation, High-Intensity Focused Ultrasound (HIFU), and irreversible electroporation.
Increasing Demand for Minimally Invasive Procedures
The tumor ablation market will expand at a faster rate if surgeons and patients continue to favor minimally invasive procedures. These procedures have a number of advantages, including shorter turnaround times, faster recovery times, patient comfort, and others.
In addition, it is anticipated that the market will expand more rapidly as the incidence of cancer rises. The market is expected to expand as a result of the growing number of elderly people worldwide and the prevalence of sedentary lifestyles. The growth rate of the tumor ablation market will be cushioned by other significant factors, such as the implementation of favorable government policies for cancer awareness and treatment methods.
Side Effects Associated with Ablation Treatment
The market’s growth rate will be hampered by the side effects of ablation treatment, like abdominal pain, bleeding into the chest cavity or abdomen, liver infection, and others. However, the market for tumor ablation is anticipated to be constrained by stringent government regulations and high treatment costs. Also, the supply chain will be severely affected by the COVID-19 outbreak, and a lack of awareness of people about tumor ablation will hinder the growth of the tumor ablation market.
Growing awareness about ablation procedures
Increasing awareness about ablation procedures over surgical procedures and conventional therapeutics is expected to boost the growth of this market and will provide beneficial opportunities for the tumor ablation market growth. In addition, over the forecast period, the tumor ablation market will grow as a result of an increase in the number of new products introduced and emerging markets.
The Radiofrequency Tumor Ablation Technology Segment Accounted for The Highest Revenue Share
In 2022, radiofrequency tumor ablation accounted for over 37% of all revenue. The dominance can be credited to its potential benefits like particularity and effectiveness in strong growth removal strategies in the liver and kidneys. With multiple electrodes placed at various locations, radiofrequency ablation can also be used to treat various tumors simultaneously, enhancing procedural efficiency. The rate of adoption of cutting-edge tumor ablation methods is anticipated to rise as a result.
It is anticipated that microwave ablation technology will experience profitable growth. Unlike an electric current in a radiofrequency ablation device, the energy of a microwave ablation device creates an EMF. The utilization of this technology in tissues with the least electrical conductivity, such as the lungs and bones, is enhanced as a result of this. The larger tumor ablation volume, less ablation pain, consistent high temperature, and optimal heating of the cystic mass are among the technology’s main advantages. It is anticipated that these advantages will help this market expand. In addition, the segment is anticipated to be driven by shorter procedure times (between 5 and 10 minutes), shorter hospital stays, and increased efficacy with fewer complications.
Mode of Treatment Analysis
The Surgical Ablation Segment Held the Largest Revenue Share
In 2022, the surgical ablation sector had a revenue share of over 42%. The factors that are estimated to fuel segment growth are the lack of advanced tumor ablation methods for these particular organs and the increased prevalence of breast and liver cancer. Over the forecast period, lucrative growth is anticipated in the percutaneous ablation sector. These procedures speed up recovery, leave fewer scars, and are safer. In addition, the segment’s demand is anticipated to be further boosted by factors such as patient comfort, short surgical times, and cost-effectiveness. However, it is anticipated that the system’s higher complications will limit its expansion, particularly in hospitals with a lack of skilled personnel.
The NCBI report says that unfavorable tumor locations make percutaneous ablations impossible for 25-55% of patients. Percutaneous ablation has a higher rate of tumor recurrence because deep-seated tumors are not sufficiently eradicated. Due to the high risk of tumor recurrence, percutaneous ablation should not be used to treat lesions that are close to the heart, gallbladder, bile duct, and gastrointestinal tract. Therefore, laparoscopic ablation is effective in achieving long-term results while maintaining minimal invasiveness in such a situation. During the forecast period, this is anticipated to accelerate the expansion of the laparoscopic ablation market.
Liver Cancer Dominated the Market
With a revenue share of more than 22% in 2022, liver cancer dominated the market. The rising prevalence of primary liver cancer and bile duct cancer is responsible for this. The market is divided into breast cancer, liver cancer, kidney cancer, prostate cancer, lung cancer, and others based on application. Other cancers include bone metastasis and nose, ear, and throat cancer, among others. Market expansion is expected to be facilitated by the availability of cutting-edge treatments and rising cancer rates.
During the forecast period, it is anticipated that the market for renal or kidney cancer will expand profitably. The treatment of renal tumors is made possible by the technology of radiofrequency and microwave ablation. Patients with tumors less than 4 centimeters in size, solitary kidneys, and a slow rate of recovery after surgery are candidates for kidney tumor ablation. During the forecast period, it is anticipated that the market for lung tumor ablation will expand rapidly. The disease’s rising prevalence is responsible for this.
The Hospital Segment Dominated the Global Tumor Ablation Market.
The tumor ablation market has been segmented by end-user into hospitals, specialty clinics, ambulatory surgery centers, and other end-users. Due to the presence of experienced and well-equipped professionals, the hospital segment is anticipated to be the fastest-growing segment during the forecast period of 2023-2032. In 2022, this segment dominated the market.
Key Market Segments
Based on Technology
- Microwave Ablation
- Radiofrequency Ablation
- Irreversible Electroporation Ablation
- Other Ablation Technologies
Based on the Mode of Treatment
- Laparoscopic Ablation
- Surgical Ablation
- Percutaneous Ablation
Based on Application
- Liver Cancer
- Kidney Cancer
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Other Applications
Based on End-User
- Specialty Clinics
- Ambulatory Surgery Centers
- Other End-Users
North America Dominates the Global Tumor Ablation Market During the Forecast Period
In 2022, the market was dominated by North America, which had a revenue share of 37%. Government support for high-quality healthcare, the availability of reimbursements, high purchasing power parity, and the rising incidence of cancer are major drivers of this region’s expansion. For instance, the Patient Protection and Affordable Care Act (PPACA) in the United States decrease the cost of healthcare for individuals and the government by promoting healthcare affordability and quality through health coverage policies. Another important driver of growth is the precision medicine initiative, which aims to develop individualized treatment plans for specific diseases. As a result, it is anticipated that such government initiatives will enhance the healthcare system as a whole, thereby boosting market expansion.
Europe accounted for a significant share of the revenue. This expansion was facilitated by a greater proportion of public funding for the healthcare system in Europe. In addition, it is anticipated that government support for cancer control and the expanding geriatric population will boost market expansion in this region. The European Cancer Observatory, for instance, aims to raise awareness about cancer and advance less invasive therapeutic options and early diagnostic methods.
During the forecast period, APAC is anticipated to experience the highest rate of growth. Opportunities for growth are presented by the growing numbers of patients and primary healthcare providers in rapidly emerging economies like China and India. Additionally, healthcare utilization is rising in the Asia-Pacific region due to government support. For instance, the Health Minister Cancer Patient Fund (HMCPF) scheme in India provides financial assistance to low-income cancer patients. Over the forecast period, this is expected to drive the demand for this device in this region.
- North America
- The US
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Latin America
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Key Players Analysis
Boston Scientific Corporation Received Health Canada approval for its Advanced Cryoablation System Named ICEfx™
In order to gain a significant share of the tumor ablative market, major companies are making significant investments in research and development. For instance, Boston Scientific Corporation got approval from Health Canada in August 2019 for its advanced cryoablation system known as ICEfx™. The device is a powerful alternative to the current cryoablation systems and has a smaller footprint, is effective, and is portable. A few of the prominent players in the market are SonaCare Medical LLC, EDAP TMS S.A., AngioDynamics Inc., Neuwave Medical, Inc., BVM Medical Limited, Galil Medical, Inc., Healthtronics Inc, and other major players.
Market Key Players
Listed below are some of the most prominent global tumor ablation players.
- Medtronic Plc
- Boston Scientific Corporation
- Galil Medical Inc.
- HealthTronics, Inc.
- Ethicon, Inc.
- Misonix, Inc.
- Mermaid Medical
- Other Key Players.
Key Industry developments
- In June 2022– IceCure Medical Ltd. filed a regulatory application for the approval of ProSense, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of benign and cancerous tumors by freezing. The primary focus areas are kidney, bone, breast, and lung cancer.
- In September 2021- Francis Medical, Inc., a privately held medical device company that is working on a novel and exclusive water vapor ablation therapy for the treatment of kidney, prostate, and bladder cancer, closed its USD 55 million Series B equity financing.
Report Features Description Market Value (2022) USD 1,333 Mn Forecast Revenue (2032) USD 4,389 Mn CAGR (2023-2032) 13% Base Year for Estimation 2022 Historic Period 2016-2021 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Technology- Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, and Other Ablation Technologies; By Mode of Treatment- Laparoscopic Ablation, Surgical Ablation, and Percutaneous Ablation; By Application- Liver Cancer, Kidney Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, and Other Applications; and By End-User- Speciality Clinics, Ambulatory Surgery Centers, Hospitals, and Other End-Users. Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; The Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA. Competitive Landscape Angiodynamics, Medtronic Plc, Boston Scientific Corporation, Galil Medical Inc., HealthTronics, Inc., Ethicon, Inc., Misonix, Inc., Mermaid Medical, and Other Key Players. Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)Q: What are the segments covered in the tumor ablation market report?
A: Market.US has segmented the tumor ablation market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By technology, the market has been segmented into radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, other ablation technologies. By application the market has been further divided into Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Cancers.Q: Who are the key players in the tumor ablation market?
A: Angiodynamics (Covidien), Boston Scientific Corporation, Medtronic Plc, Ethicon, Inc., Galil Medical Inc., Misonix Inc., HealthTronics, Mermaid Medical, Theraclion, Chongqing Haifu Medical Technology Co. Ltd., HS Hospital Service S.P.A, EDAP TMS S.A., Other Key Players, are the key vendors in the tumor ablation market.Q: Which region is more attractive for vendors in the tumor ablation market?
A: North America have accounted the highest revenue share of 30.0% among other regions. Therefore, North America’s tumor ablation market is expected to garner significant business opportunities for the vendors during the forecast period.Q: What are the key markets for tumor ablation?
A: Key markets for tumor ablation are the U.S., Mexico, China, Japan, Germany, UK, India, South Korea, Brazil, and France.Q: Which segment has the largest share in the tumor ablation market?
A: In the tumor ablation market, vendors should focus on grabbing business opportunities from the radiofrequency tumor ablation segment as it accounted for the largest market share in the base year.
- Medtronic Plc
- Boston Scientific Corporation Company Profile
- Galil Medical Inc.
- HealthTronics, Inc.
- Ethicon, Inc.
- Misonix, Inc.
- Mermaid Medical
- Other Key Players.
| Single User
USD / per unit
| Multi User
USD / per unit
| Corporate User
USD / per unit
|Report Library Access
|Data Set (Excel)
|Company Profile Library Access
|up to 10 hrs work
|up to 30 hrs work
|up to 20 hrs
|up to 40 hrs
|up to 50 hrs
|Up to 20% off on next purchase
|Up to 25% off on next purchase
|Up to 30% off on next purchase
|Buy Now ($ 3,499)
|Buy Now ($ 4,299)
|Buy Now ($ 4,999)